Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Multicenter Study of Hematopoietic Stem Cell Transplant of ECT-001-Expanded Cord Blood With a Reduced Toxicity Conditioning Regimen in Patients With Severe Sickle Cell Disease

Next Previous
Search
Trial Profile

A Phase I Multicenter Study of Hematopoietic Stem Cell Transplant of ECT-001-Expanded Cord Blood With a Reduced Toxicity Conditioning Regimen in Patients With Severe Sickle Cell Disease

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dorocubicel-ExCellThera (Primary)
  • Indications Graft-versus-host disease; Sickle cell anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ExCellThera

    • Most Recent Events

    • 29 Jun 2022 Status changed from recruiting to withdrawn prior to enrolment. Reason the study was stopped: Preference given to gene therapy approaches by the SCD research community and patients' associations.
    • 16 Jul 2021 Status changed from not yet recruiting to recruiting.
    • 12 Jul 2021 Planned initiation date changed from 1 Jun 2021 to 31 Jul 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top